Blue Water Acquisition — Clarus Therapeutics Holdings — Investor Presentation (September 2021)
28 slides from Blue Water Acquisition's investor presentation, Sep 20, 2021

Slide 1: Corporate Presentation September 2021: Androgen and Metabolic Therapies for Better Health
1 CORPORATE PRESENTATION SEPTEMBER 2021 ANDROGEN AND METABOLIC THERAPIES FOR BETTER HEALTH

Slide 2: Disclaimer
2 DISCLAIMER Certain statements in this presentation constitute “forward - looking statements” for purposes of the federal securities laws. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predic

Slide 3: Investment Thesis
3 3 1 2 6 3 4 Clarus markets JATENZO ® , an FDA approved, first - in - class oral testosterone (T) replacement therapy (“TRT”) with strong potential to capture & grow market share. Each JATENZO market share point in the U.S. is expected to yield ~$33MM in annual net sales. With adequate support , we

Slide 4: Clarus Leadership Team and Board of Directors
4 ROBERT DUDLEY, PH.D President & CEO • Over 30 years experience in TRT field • Clarus co - founder • Extensive R&D experience and FDA regulatory experience • Co - inventor and developer of AndroGel 1% • Co - inventor of JATENZO • Track record of success with public company • Abbott, Solvay, Unimed

Slide 5: The JATENZO Opportunity
5 THE JATENZO ® OPPORTUNITY

Slide 6: U.S. Testosterone Market Is Large & Growing
6 6 U. S. TESTOSTERONE (T) MARKET IS LARGE & GROWING T DEFICIENCY IN MEN (HYPOGONADISM) STILL HAS AREAS OF UNMET NEED Diagnosed Population Opportunity to educate men about the signs and symptoms of hypogonadism due to certain medical conditions References: U.S. Census (2019); Int J of Clin Pract (20

Slide 7: Importance of an Oral T Option
7 7 Current Non - oral Treatments Pose Administration Challenges The Cycle of Discontinuation More than 95,000 men change TRTs at least once per year* • Injection pain • Procedures • Mess, drying time • Transference to partner/kids • Skin irritation • Gum irritation/disorders • Nasal irritation IMPO

Slide 8: The JATENZO Opportunity: First Oral T of Its Kind Approved by FDA
8 8 THE JATENZO OPPORTUNITY FIRST ORAL T OF ITS KIND APPROVED BY FDA – A LONG - AWAITED ADVANC E! CONVENIENT • Easy - to - swallow soft gel taken BID with food (twice daily) • Dose adjustable, if necessary EFFECTIVE • 87% of men achieved T levels in normal range • Restored T levels to mid - normal r

Slide 9: JATENZO Product Differentiators
9 9 JATENZO PRODUCT DIFFERENTIATORS A SAFE ORAL TRT WITHOUT LIVER TOXICITY THAT ADDRESSES COMMON CON CERNS SEEN WITH INJECTIONS AND GELS LACK OF A SAFE AND EFFECTIVE ORAL TESTOSTERONE INJECTABLE T PRODUCTS CAN BE PAINFUL AND CARRY SIGNIFICANT RISKS TOPICAL T PRODUCTS ARE MESSY AND CARRY RISK OF TRAN

Slide 10: JATENZO Clinical Benefits
10 10 Increased Bone Mineral Density Improved Body Composition Improved Psychosexual Symptoms Increased Free (Active) Testosterone References: Swerdloff, RS and Dudley, RE. Ther Adv Ur o l 2020; 12: 1 - 16. Swerdloff, RS, et al. J Clin Endocrinol Metab 2020:105: 1 - 17

Slide 11: JATENZO Safety Profile Consistent with TRT Class
11 Adverse Reactions ≥ 2% in 4 - Month Pivotal Trial of JATENZO 1 JATENZO WAS SHOWN TO BE SAFE AND WELL - TOLERATED JATENZO SAFETY PROFILE CONSISTENT WITH TRT CLASS References: 1 Swerdloff, RS, et al. J Clin Endocrinol Metab 2020:105: 1 - 17; 2 Swerdloff, RS and Dudley, RE. Ther Adv Ur o l 2020; 12:

Slide 12: Maximizing JATENZO's Commercial Potential
12 MAXIMIZING JATENZO’S COMMERCIAL POTENTIAL

Slide 13: TRT Market Is Large & Growing
13 TRT MARKET IS LARGE & GROWING HEALTHCARE PROVIDERS CONTINUE TO ACTIVELY DIAGNOSE AND TREAT HYP OGONADAL PATIENTS 13 • Market Volume • High volume of ~8MM TRxs annually • Growth Rate • 7.5% 5 - year CAGR* • Valuable to Clarus • Payers reimburse branded agents • Each JATENZO share point is ~ $33MM

Slide 14: JATENZO Is Poised to Accelerate Growth
14 JATENZO IS POISED TO ACCELERATE GROWTH THE COMMERCIAL FOUNDATION HAS BEEN ESTABLISHED 14 55 Territories 62% Coverage of TRT Market Endo, URO, and PCP Top Deciles 5 National Account Managers Commercial, Part D, Medicaid Health Care Provider (HCP ) Education; Patient Advertising Data Source: Sympho

Slide 15: JATENZO Has Competitive & Affordable Coverage
15 JATENZO HAS COMPETITIVE & AFFORDABLE COVERAGE JATENZO IS COVERED ACROSS ALL PAYER CHANNELS 15 Data Sources: Competitive data using MMIT, (as of 8/26/2021) Payer Coverage Across ALL payer channels* * Payer Channels include Commercial, Medicare Part D, Medicaid, and Health Exchanges 90% 64% 61% 68%

Slide 16: DTC Advertising Will Be a Key Growth Driver
16 DTC ADVERTISING WILL BE A KEY GROWTH DRIVER BY COMMUNICATING TO CONSUMERS, WE BELIEVE PATIENTS WILL DRIVE JA TENZO CONVERSATIONS WITH HCP s ) 16 Patient Awareness Patient Demand

Slide 17: Expanded Sales Force Reach Increases HCP Awareness
17 EXPANDED SALES FORCE REACH INCREASES HCP AWARENESS … AND WHEN COMBINED WITH DTC ADVERTISING, FOSTERS APPROPRIATE DIA LOG BETWEEN PATIENTS AND HCP s 17 Current 55 Territories Future Planned Expansion

Slide 18: Patient Hub Facilitates Effective JATENZO Distribution
18 PATIENT ‘HUB’ CREATES KEY POINT OF PATIENT CONTACT TO FACILITATE EFFECTIVE JATENZO DISTRIBUTION HUB ASSISTS WITH DRUG BENEFITS, PRIOR AUTHORIZATIONS, JATENZO R x DELIVERY, CO - PAY SUPPORT, AND PATIENT EDUCATION 18 Supports patient j ourney … … all the way to product fulfillment

Slide 19: Focus on Patient Designed to Drive JATENZO Demand
19 FOCUS ON PATIENT DESIGNED TO DRIVE JATENZO DEMAND 19 Telemedicine Find - a - Doc Targeted HCPs Clarus Expanded Sales Force Increases “Reach and Frequency” Direct Ship Patient Patient Easily Reorders JATENZO Patient HUB Service Patient Sees JATENZO DTC Ad Patient Visits JATENZO Website

Slide 20: Growth Opportunities
20 GROWTH OPPORTUNITIES

Slide 21: Three-Pronged Approach to Growing a Strong Business
21 3 - PRONGED APPROACH TO GROWING STRONG BUSINESS 21 JATENZO LIFE - CYCLE MANAGEMENT AND BUSINESS DEVELOPMENT PLANNED T O GROW BUISNESS JATENZO LIFE - CYCLE MANGEMENT ESTABLISH R & D PIPELINE BUSINESS DEVELOPMENT Hypogonadism ~8 MM Prescriptions/ yr F - T - M Transgender 700K Male Patients Chronic

Slide 22: Testosterone + Anastrozole (CLAR-121)
22 • Painful, debilitating inflammation of breast tissue – predominantly in women • No effective pharmaceutical intervention; often results in disfiguring surgery • CLAR - 121 mechanism - of - action is to activate AR - dependent anti - inflammatory mechanism in breast tissue • History of CLAR - 121

Slide 23: CoQ + Caspofungin for CoQ Deficiencies
23 CoQ 10 + CASPOFUNGIN FOR CoQ 10 DEFICIENCIES 1 Wang, Y. and Hekimi, S. Micellization of coenzyme Q by the fungicide caspofungin allows for safe intravenous administration t o reach extreme supraphysiological concentrations . Redox Biol 2020; 36: 101680.; Figures from: Stefely JA and Pagliarini DJ

Slide 24: R&D Programs & Milestones
24 R & D PROGRAMS & MILESTONES 24 R & D Program Description / Remark Clinical Testing Phase Projected Initiation JATENZO®: CKD Treatment of hypogonadal men with chronic kidney disease / labeling expansion Phase 4 2H 2021 Once - Daily Oral TU Once - daily oral TU product to treat male hypogonadism /

Slide 25: Intellectual Property & Exclusivity Pathways
25 INTELLECTUAL PROPERTY & EXCLUSIVITY PATHWAYS • Robust JATENZO IP Estate: • Clear Pathway to Issued IP and Market Exclusivity for T+A (CLAR - 121) and CoQ 10 + CF (CLAR - 222): - Patent applications pending in U.S. and major non - U.S. pharma markets - Potential for 5 - Year Hatch - Waxman market

Slide 26: Financial Highlights
26 FINANCIAL HIGHLIGHTS

Slide 27: Financial Highlights
27 FINANCIAL HIGHLIGHTS 27 Publicly Traded (9/10/21) NASDAQ: CRXT Current Cash (6/30/21) $10.3M Gross Cash from Business Combination $25.3M Outstanding Shares (9/9/21) 21.7M

Slide 28: Key Takeaways
Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 28 2 8 » Experienced team with track record of success developing and commercializing innovative therapies in our target markets
Source: SEC EDGAR · 8-K filed Sep 20, 2021



